Camurus AB

Camurus AB is a Swedish pharmaceutical and biotechnology business focused on the commercialization of drugs for the treatment of serious and chronic diseases . The company was founded in 1991 and has its headquarters in the southern university town of Lund in the Medicon Valley, listed on Nasdaq Stockholm as a Mid Cap company.

Experienced lipid-phase structure scientists from the fields of biochemistry, food and pharmaceuticals have developed Camurus. The business offers advanced drug delivery methods at the nanoscale to create highly effective treatments.

Camurus wants to work with pharmaceutical and biotech companies around the world to enable and enhance the supply of a wide range of medicinal ingredients. These substances, including peptides, proteins, and insoluble small molecules, are delivered using lipid nanocarriers, long-acting depots, and other methods that increase intravenous absorption, through skin and by mouth.

Healthcare needs in the unusual areas of growth hormone, oncology, cancer supportive care, metabolic disease and drug addiction are the goals of Camurus' in-house product range. British investors selected Camurus as the best private biotech company in the Medicon Valley in 2007 after evaluating six nominated private companies. The business received the 2007 Rigorous Finance Award. The CPhI Pharma Award for Best Innovation in Formulation was presented to Camurus in 2013.

Founded: 1991

Number of employees: over 180 employees

Headquarters: Lund, Sweden
Website: https://www.camurus.com/